Topadur Pharma AG

TOPADUR is a a clinical-stage biopharmaceutical start-up company developing disruptive therapies for aging diseases. The company developed the DualTOP™ technology platform consisting of new dual-acting drugs that increase the levels of cGMP to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. TOPADUR’s R&D portfolio consists of promising candidates in regenerative medicine, oncology, ophthalmology and medical aesthetics. The DualTOP™ technology will contribute to promoting long healthy life. Topadur Pharma is preparing for an IPO in Switzerland for 2024/25